MedTrace Logo

"Treatment of Active HBV With γδT Cells" Clinical Trial Protocol

NCT03113058 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-21

No results posted yet for this study

Summary

To evaluate the safety and anti-HBV efficacy of γδT cells.

Conditions

  • Adoptive Treatment for Hepatitis B With γδT Cells

Interventions

COMBINATION_PRODUCT

Adoptive transfer of γδT cells

Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).

Sponsors & Collaborators

  • Guagnzhou Qiaokang Hospital

    collaborator UNKNOWN

  • Jinan University Guangzhou

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-02
Primary Completion
2018-10-05
Completion
2018-11-01

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03113058 on ClinicalTrials.gov